نتایج جستجو برای: پروبیوتیک abt 10
تعداد نتایج: 1019339 فیلتر نتایج به سال:
We determined in vitro susceptibilities for ABT-492 and other antimicrobials against Mycoplasma pneumoniae, Mycoplasma fermentans, Mycoplasma hominis, and Ureaplasma species. ABT-492 MICs were < or =1 microg/ml, and the agent was bactericidal against selected isolates of M. pneumoniae and M. hominis. ABT-492 has potential for treatment of infections due to these microorganisms.
Abstract Atlantic bluefin tuna (ABT, Thunnus thynnus; Linneaus, 1758) is an ecologically important apex-predator with high commercial value. They were once common off the coast of United Kingdom (UK), before disappearing in 1960s. In regions lacking fisheries for ABT, such as UK and Ireland, spatial data can be scarce. these cases, sightings bycatch databases offset information shortfalls. Here...
Thunnus thynnus (Atlantic bluefin tuna, ABT) and other tuna species reproduce in the Mediterranean Sea during summer period. Despite Central Sea, Strait of Sicily particular, being a key spawning site for many species, little is known on effects oceanographic variability their larval distribution this area. The abundance presence-absence specimens three (ABT, bullet albacore) were modeled order...
OBJECTIVE To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. DESIGN Phase 1 dose-escalation clinical trial. SETTING Comprehensive Cancer Center, University of Alabama at Birmingham. Patients A total of 23 patients with newl...
ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 micromol/L) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. The inhibition prof...
BACKGROUND Autologous blood transfusion (ABT) is currently considered the safest transfusion, since the risks of allogeneic immunological reaction and viral transmission are theoretically null. Although its use has declined in Western countries in the recent decade, it has been progressively expanded in Japan. With the widening of the concept of patient blood management (PBM), which aims to pre...
This article summarizes presentations of a symposium examining the potential impact of activity-based therapies (ABT) in promoting neurological and functional recovery after spinal cord injury (SCI). The symposium addressed 3 key questions concerning activity-based therapy in SCI: (1) What clinical approaches are used? (2) Is there empirical evidence supporting efficacy of ABT in promoting neur...
The in vitro activities of ABT 773, telithromycin (HMR 3647), azithromycin, clarithromycin, erythromycin, and levofloxacin were tested against 20 strains of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by ABT 773 were 0.015 microg/ml (range, 0.008 to 0.015 microg/ml). ABT 773 was the...
The comparative in vitro activities of ABT-773 against 207 aerobic and 162 anaerobic antral sinus puncture isolates showed that erythromycin-resistant pneumococcal strains were susceptible to ABT-773 (< or =0.125 microg/ml); the MIC at which 90% of the isolates tested were inhibited for Haemophilus influenzae and other Haemophilus spp. was 4 microg/ml; and all Moraxella spp. and beta-lactamase-...
ABT-888 is a potent, orally bioavailable inhibitor of PARP-1 and PARP-2 (potency ≤5nM in vitro). ABT-888 does not inhibit other NAD-binding enzymes and has minimal CYP450 inhibition and induction. ABT-888 increases tumor growth delay resulting from radiation and DNA-damaging agents. It shows broad spectrum of chemoand radiopotentiation. The ability to potentiate temozolomide (TMZ) and develop a...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید